Shilpa Medicare Ltd (SHME)

BSE
Currency in INR
754.10
+14.15(+1.91%)
Closed
SHME Scorecard
Full Analysis
Net income is expected to grow this year
Earnings results expected in 4 days
Fair Value
Day's Range
736.20765.00
52 wk Range
357.95959.95
Key Statistics
Edit
Bid/Ask
742.25 / 748.40
Prev. Close
739.95
Open
739.45
Day's Range
736.2-765
52 wk Range
357.95-959.95
Volume
5.96K
Average Volume (3m)
21.52K
1-Year Change
104.77%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SHME Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
1,208.00
Upside
+60.19%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Shilpa Medicare Ltd Company Profile

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company provides intermediates; high-purity multi-cyclic and long-chain peptides; specialty and biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Employees
1007
Market
India

Compare SHME to Peers and Sector

Metrics to compare
SHME
Peers
Sector
Relationship
P/E Ratio
105.2x27.5x−0.6x
PEG Ratio
0.180.570.00
Price/Book
2.8x3.3x2.6x
Price / LTM Sales
5.3x3.1x3.1x
Upside (Analyst Target)
60.2%6.4%51.7%
Fair Value Upside
Unlock−11.7%7.5%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1,208.00
(+60.19% Upside)

Earnings

Latest Release
Nov 13, 2024
EPS / Forecast
1.80 / --
Revenue / Forecast
3.44B / --
EPS Revisions
Last 90 days

FAQ

What Is the Shilpa Medicare Ltd (SHME) Stock Price Today?

The Shilpa Medicare Ltd stock price today is 754.10.

What Stock Exchange Does Shilpa Medicare Ltd Trade On?

Shilpa Medicare Ltd is listed and trades on the BSE stock exchange.

What Is the Stock Symbol for Shilpa Medicare Ltd?

The stock symbol for Shilpa Medicare Ltd is "SHME."

Does Shilpa Medicare Ltd Pay Dividends? What’s The Current Dividend Yield?

The Shilpa Medicare Ltd dividend yield is 0.31%.

What Is the Shilpa Medicare Ltd Market Cap?

As of today, Shilpa Medicare Ltd market cap is 65.46B.

What is Shilpa Medicare Ltd Earnings Per Share?

The Shilpa Medicare Ltd EPS is 6.66.

What Is the Next Shilpa Medicare Ltd Earnings Date?

Shilpa Medicare Ltd will release its next earnings report on 09 Feb 2025.

From a Technical Analysis Perspective, Is SHME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.